NASDAQ:IPSC Century Therapeutics (IPSC) Stock Price, News & Analysis $1.86 0.00 (0.00%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.86 0.00 (0.00%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Century Therapeutics Stock (NASDAQ:IPSC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Century Therapeutics alerts:Sign Up Key Stats Today's Range$1.82▼$1.8850-Day Range$1.86▼$2.2652-Week Range$0.44▼$3.04Volume1.37 million shsAverage Volume459,361 shsMarket Capitalization$336.79 millionP/E RatioN/ADividend YieldN/APrice Target$4.75Consensus RatingHold Company Overview Century Therapeutics, Inc. is a biotechnology company focused on developing allogeneic cell therapies for cancer and other serious diseases. The company uses induced pluripotent stem cell (iPSC) technology, gene editing and cell-engineering methods to create potentially off-the-shelf immune cell therapies designed to recognize and eliminate diseased cells. Its pipeline has included engineered natural killer (NK) cell and T-cell programs targeting blood cancers. Among its leading programs is CNTY-101, an allogeneic CAR NK cell therapy directed at CD19, a target associated with certain B-cell malignancies. Century has also developed additional programs intended to address limitations of existing cell therapies, including challenges related to manufacturing, availability and treatment durability. Century Therapeutics was founded in 2018 and is headquartered in Philadelphia, Pennsylvania. The company’s research and development activities are primarily focused on advancing cell therapy candidates through clinical development for patients in the United States and, where applicable, other regulated markets. Its therapies are investigational and have not been established as safe or effective for general commercial use.AI Generated. May Contain Errors. Read More Century Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreIPSC MarketRank™: Century Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 760th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCentury Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCentury Therapeutics has a consensus price target of $4.75, representing about 155.4% upside from its current price of $1.86.Amount of Analyst CoverageCentury Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Century Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Century Therapeutics are expected to remain at ($0.51) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Century Therapeutics is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Century Therapeutics is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Century Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.71% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 70.64, which indicates bearish sentiment.Change versus previous monthShort interest in Century Therapeutics has recently increased by 0.54%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment-0.24 News SentimentCentury Therapeutics has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Century Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for IPSC on MarketBeat in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,808.00 in company stock.Percentage Held by Insiders2.40% of the stock of Century Therapeutics is held by insiders.Percentage Held by Institutions50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Century Therapeutics' insider trading history. Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IPSC Stock News HeadlinesCentury Therapeutics (NASDAQ:IPSC) Raised to "Hold" at Wall Street ZenSeptember 12, 2026 | americanbankingnews.comCentury Therapeutics Appoints IECURE CEO Joseph Truitt To Board As CNTY-813 Nears IND FilingSeptember 10, 2026 | rttnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Century Therapeutics Appoints Joseph Truitt to Board of DirectorsSeptember 9, 2026 | globenewswire.comCentury Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesAugust 12, 2026 | finanznachrichten.deCentury Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesAugust 12, 2026 | globenewswire.comCentury Therapeutics (IPSC) to Present CNTY-813 Data at Scientific CongressesJuly 14, 2026 | insidermonkey.comCentury: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative PotentialJuly 9, 2026 | seekingalpha.comSee More Headlines IPSC Stock Analysis - Frequently Asked Questions How have IPSC shares performed this year? Century Therapeutics' stock was trading at $0.9948 at the start of the year. Since then, IPSC shares have increased by 87.0% and is now trading at $1.86. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) posted its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.06. When did Century Therapeutics IPO? Century Therapeutics (IPSC) raised $200 million in an initial public offering on Thursday, June 17th 2021. The company issued 10,550,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO. Who are Century Therapeutics' major shareholders? Century Therapeutics' top institutional shareholders include BlackRock Inc. (4.49%), Seven Fleet Capital Management LP (2.41%), Trails Edge Capital Partners LP (2.29%) and Spruce Street Capital LP (2.25%). Insiders that own company stock include Brent Pfeiffenberger, Chad Cowan, Gregory Russotti, Douglas Carr and Adrienne Farid. View institutional ownership trends. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Century Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Century Therapeutics investors own include The RMR Group (RMR), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/12/2026Today9/21/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IPSC's financial health is in the Green zone, according to TradeSmith. IPSC has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IPSC CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees78Year Founded2018Price Target and Rating Average Price Target for Century Therapeutics$4.75 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+155.4%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.58 million Net MarginsN/A Pretax Margin-8.84% Return on Equity-49.51% Return on Assets-38.09% Debt Debt-to-Equity RatioN/A Current Ratio8.28 Quick Ratio8.28 Sales & Book Value Annual Sales$109.16 million Price / Sales3.09 Cash Flow$0.01 per share Price / Cash Flow139.85 Book Value$1.82 per share Price / Book1.02Miscellaneous Outstanding Shares181,070,000Free Float176,729,000Market Cap$336.79 million OptionableOptionable Beta1.59 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:IPSC) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
